PATENT CLAIM ANALYSIS

Application Number: 16208413
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "940000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 6):
The method of  claim 1 , wherein the neridronic acid is administered in a dosage form that is a dispersion, a suspension, or a solution.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15647140', '15840066', '15710759', '15716334', '15357932']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8535443172545996
- 35 USC 102 Novelty (BERT): 0.6232462295460158
- Combined Prediction Score: 0.8305145084837412
- Mean Citation Score: 601.5673320000002
- Max Citation Score: 609.73956
- Similarity Product: 520.9780762219191

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test